Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

ClinicalTrials.gov ID: NCT00976820

Public ClinicalTrials.gov record NCT00976820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age

Study identification

NCT ID
NCT00976820
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
323 participants

Conditions and interventions

Conditions

Interventions

  • GSK2340274A Biological
  • GSK2340273A Biological

Biological

Eligibility (public fields only)

Age range
6 Months to 8 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 19, 2009
Primary completion
Mar 20, 2011
Completion
Mar 20, 2011
Last update posted
Dec 11, 2017

2009 – 2011

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
GSK Investigational Site Conway Arkansas 72034
GSK Investigational Site Little Rock Arkansas 72202
GSK Investigational Site Sacramento California 95816
GSK Investigational Site San Francisco California 94102
GSK Investigational Site Arkansas City Kansas 67005
GSK Investigational Site Wichita Kansas 67205
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site Saint Paul Minnesota 55108
GSK Investigational Site Omaha Nebraska 68134
GSK Investigational Site Cleveland Ohio 44121
GSK Investigational Site Kingsport Tennessee 37660
GSK Investigational Site Austin Texas 78705
GSK Investigational Site Fort Worth Texas 76135
GSK Investigational Site San Angelo Texas 76904
GSK Investigational Site Orem Utah 84057
GSK Investigational Site South Jordan Utah 84095

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00976820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 11, 2017 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00976820 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →